Krystal Biotech Inc’s recently made public that its President, R&D Krishnan Suma unloaded Company’s shares for reported $4.44 million on Mar 13 ’25. In the deal valued at $177.79 per share,25,000 shares were sold. As a result of this transaction, Krishnan Suma now holds 1,533,056 shares worth roughly $199.33 million.
Then, Krishnan Suma sold 25,000 shares, generating $4,444,761 in total proceeds. Upon selling the shares at $177.79, the President, R&D now owns 1,463,711 shares.
Before that, Krishnan Krish S sold 25,000 shares. Krystal Biotech Inc shares valued at $4,444,763 were divested by the President and CEO at a price of $177.79 per share. As a result of the transaction, Krishnan Krish S now holds 1,533,056 shares, worth roughly $199.33 million.
Jefferies initiated its Krystal Biotech Inc [KRYS] rating to a Buy in a research note published on March 05, 2025; the price target was $245. A number of analysts have revised their coverage, including Citigroup’s analysts, who decreased its forecast for the stock in early August from “a Buy” to “a Neutral”. Goldman began covering KRYS with “Buy” recommendation on November 20, 2023. Cantor Fitzgerald started covering the stock on October 24, 2023. It rated KRYS as “an Overweight”.
Price Performance Review of KRYS
On Tuesday, Krystal Biotech Inc [NASDAQ:KRYS] saw its stock fall -2.27% to $130.02. Over the last five days, the stock has lost -5.93%. Krystal Biotech Inc shares have fallen nearly -17.00% since the year began. Nevertheless, the stocks have fallen -28.84% over the past one year. While a 52-week high of $219.34 was reached on 03/25/25, a 52-week low of $122.80 was recorded on 05/23/25.
Levels Of Support And Resistance For KRYS Stock
The 24-hour chart illustrates a support level at 128.50, which if violated will result in even more drops to 126.99. On the upside, there is a resistance level at 132.22. A further resistance level may holdings at 134.43.
The most recent change occurred on October 12, 2023 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $160 price target.
